Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Sexually Transmitted Infections
|
July 20, 2019
Response to 'Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017' by Checchi <i>et al</i>
Valérie Berlaimont, Sarah Welby
Vaccine
|
July 26, 2016
Letter to the Editor; P. Van Damme et al. Vaccine 34 (2016) 757-761
Martin Ryser, Valérie Berlaimont, Attila Mihalyi
Papillomavirus Research (Amsterdam, Netherlands)
|
December 24, 2017
Letter-to-the-Editor in response to "Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001."
Martin Ryser, Adrienne Guignard, Valérie Berlaimont
The Journal of Infectious Diseases
|
September 22, 2017
Reply to Poddighe
Louise Stevenson, L-M Huang, Valérie Berlaimont, et al.
Human Vaccines & Immunotherapeutics
|
January 18, 2020
Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules
Marco Costantini, Andrea Callegaro, Jiří Beran, et al.
Human Vaccines & Immunotherapeutics
|
August 19, 2020
Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules"
Marco Costantini, Andrea Callegaro, Jiří Beran, et al.
Vaccine
|
September 17, 2021
Hexavalent vaccines: What can we learn from head-to-head studies?
Markus Knuf, Hervé Haas, Pilar Garcia-Corbeira, et al.
Human Vaccines & Immunotherapeutics
|
August 26, 2021
Diphtheria-tetanus-pertussis (DTP) vaccination: understanding the perspectives and expectations of parents and healthcare professionals in France and India
Pierre Bakhache, Vijay Yewale, Raunak Parikh, et al.
Expert Review of Vaccines
|
February 12, 2019
Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types
Martin Ryser, Valérie Berlaimont, Naveen Karkada, et al.
Contemporary Clinical Trials
|
December 31, 2016
Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254-258
Nicolas Folschweiller, Valérie Berlaimont, S Rachel Skinner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Sexually Transmitted Infections
|
July 20, 2019
Response to 'Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017' by Checchi <i>et al</i>
Valérie Berlaimont, Sarah Welby
Vaccine
|
July 26, 2016
Letter to the Editor; P. Van Damme et al. Vaccine 34 (2016) 757-761
Martin Ryser, Valérie Berlaimont, Attila Mihalyi
Papillomavirus Research (Amsterdam, Netherlands)
|
December 24, 2017
Letter-to-the-Editor in response to "Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001."
Martin Ryser, Adrienne Guignard, Valérie Berlaimont
The Journal of Infectious Diseases
|
September 22, 2017
Reply to Poddighe
Louise Stevenson, L-M Huang, Valérie Berlaimont, et al.
Human Vaccines & Immunotherapeutics
|
January 18, 2020
Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules
Marco Costantini, Andrea Callegaro, Jiří Beran, et al.
Human Vaccines & Immunotherapeutics
|
August 19, 2020
Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules"
Marco Costantini, Andrea Callegaro, Jiří Beran, et al.
Vaccine
|
September 17, 2021
Hexavalent vaccines: What can we learn from head-to-head studies?
Markus Knuf, Hervé Haas, Pilar Garcia-Corbeira, et al.
Human Vaccines & Immunotherapeutics
|
August 26, 2021
Diphtheria-tetanus-pertussis (DTP) vaccination: understanding the perspectives and expectations of parents and healthcare professionals in France and India
Pierre Bakhache, Vijay Yewale, Raunak Parikh, et al.
Expert Review of Vaccines
|
February 12, 2019
Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types
Martin Ryser, Valérie Berlaimont, Naveen Karkada, et al.
Contemporary Clinical Trials
|
December 31, 2016
Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254-258
Nicolas Folschweiller, Valérie Berlaimont, S Rachel Skinner, et al.
Page
of 2